Is Bioventus Inc (BVS) overvalued? · rev $573.3M
Bioventus Inc (BVS) is a medical devices company listed on US.
This page asks whether Bioventus Inc (BVS) looks expensive on cached numbers — not a short thesis.
Latest reported BVS revenue for 2024-12-31 was $573.3M. Net income was -$43.8M. Revenue was up 11.9% from 2023-12-31 to 2024-12-31. BVS currently screens at market cap $495.1M.
BVS currently screens at market cap $495.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BVS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BVS stock page for the full model, not this heading.
Not investment advice.